Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts [Yahoo! Finance]
Biomea Fusion, Inc. (BMEA)
Company Research
Source: Yahoo! Finance
Executives from Biomea Fusion (NASDAQ:BMEA) discussed the company's lead diabetes program, icovamenib, and outlined near-term clinical milestones during a recent company event hosted by an operator identified as Mike. The conversation centered on the scientific rationale for using menin inhibition in diabetes, how the company is refining patient selection and dosing in ongoing studies, and the early strategic positioning of a separate obesity program, BMF-650. Rationale for menin inhibition in diabetes Biomea's leadership emphasized that the menin target is better known to investors through oncology-focused programs, but said academic work supports a role for menin in pancreatic beta-cell biology. Ramses Erdtmann, Biomea's Founder, President and Chief Operating Officer, cited early publications including “a 2005 paper in a PNAS paper from Karnik” and described menin as “a scaffold protein” that acts as a control mechanism in the pancreas. ? Is Oracle the First of the AI Bubbles
Show less
Read more
Impact Snapshot
Event Time:
BMEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMEA alerts
High impacting Biomea Fusion, Inc. news events
Weekly update
A roundup of the hottest topics
BMEA
News
- Biomea Fusion (BMEA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $12.00 price target on the stock.MarketBeat
- Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care TherapiesGlobeNewswire
- Biomea Fusion (BMEA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BMEA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "MarketBeat
- Biomea Fusion (BMEA) had its price target raised by Citigroup Inc. from $6.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
BMEA
Earnings
- 11/4/25 - Miss
BMEA
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- 3/24/26 - Form 10-K
- BMEA's page on the SEC website